News | Cath Lab | August 05, 2016

Osprey Receives $28 Million in Funding for its Cath Lab Contrast Reduction Technology

DyeVer, Osprey, Ospray, contrast reduction system

August 5, 2016 — Osprey Medical Inc. said it received commitments from investors for approximately $28 million Australian dollars for the market expansion of its DyeVert System to reduce contrast dose administrered to patients in the cath lab. The system helps protect patients from the harmful effects of iodine-based X-ray dye (contrast) used during commonly performed angiographic imaging procedures. 

The company said the funds raised will be primarily used to expand commercialization of its DyeVert System and continue research and development of the product portfolio, including DyeVert Plus system. Money also will help ongoing clinical evaluations for scientific presentation and publication. 

“We are delighted with the oversubscribed placement. It reflects a strong endorsement from the investment community and places Osprey in a very strong position to aggressively expand its sales and marketing team in the U.S.,” said Mike McCormick, president and CEO of Osprey. “Our commercialization efforts in the U.S. have resulted in strong sales traction to date with seven quarters of consecutive growth in sales and samples.”

He said the vendor’s original sales territory, San Antonio Texas, was profitable in June 2016 with other territories following a similar sales trajectory.

For more information: www.ospreymed.com

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab| May 23, 2017
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures, SCAI, Corindus CorPath 200
News | Robotic Systems| May 16, 2017
The largest real-world study of robotic percutaneous coronary intervention (PCI) demonstrated clinical and technical...
Adept Medical Launches IR Platform, interventional radiology
Technology | Cath Lab| May 16, 2017
Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and...
Race, Gender and Socioeconomic Factors Impact PCI Outcomes, PLATINUM Diversity study, SCAI 2017
News | Cath Lab| May 15, 2017
A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Overlay Init